HCA Healthcare, Inc. (NYSE: HCA) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 13.44 | EPS (ttm) | 29.96 | Insider Own | - | Shs Outstand | 216.50M | Perf Week | 5.34% |
| Market Cap | 87.16B | Forward P/E | 12.48 | EPS next Y | 32.25 | Insider Trans | -0.03% | Shs Float | 146.40M | Perf Month | 2.38% |
| Enterprise Value | 134.92B | PEG | 0.55 | EPS next Q | 7.10 | Inst Own | - | Short Float | 3.98% | Perf Quarter | -7.33% |
| Income | 6.64B | P/S | 1.12 | EPS this Y | 1.70% | Inst Trans | - | Short Ratio | 3.66 | Perf Half Y | -16.57% |
| Sales | 78.01B | P/B | - | EPS next Y | 9.06% | ROA | 11.30% | Short Interest | 5.83M | Perf YTD | -13.77% |
| Book/sh | - | P/C | 8.06 | EPS next 5Y | 10.95% | ROE | -112.87% | 52W High | 562.08 -27.66% | Perf Year | 13.39% |
| Cash/sh | - | P/FCF | 14.53 | EPS past 3/5Y | 14.01% 21.03% | ROIC | 19.41% | 52W Low | 356.64 14.01% | Perf 3Y | 42.67% |
| Dividend Est. | 3.12 (0.77%) | EV/EBITDA | 8.52 | Sales past 3/5Y | 7.87% 7.97% | Gross Margin | 28.36% | Volatility | 3.86% 3.56% | Perf 5Y | 62.03% |
| Dividend TTM | 3.00 (0.74%) | EV/Sales | 1.73 | EPS Y/Y TTM | 32.18% | Oper. Margin | 15.48% | ATR (14) | 14.15 | Perf 10Y | 399.31% |
| Dividend Ex-Date | Sep 16, 2026 | Quick Ratio | 0.69 | Sales Y/Y TTM | 8.19% | Profit Margin | 8.77% | RSI (14) | 54.60 | Recom | 2.41 |
| Dividend Gr. 3/5Y | 8.74% 46.28% | Current Ratio | 0.78 | EPS Q/Q | 10.96% | SMA20 | 2.64% | Beta | 1.09 | Target Price | 460.18 |
| Payout | 9.97% | Debt/Eq | - | Sales Q/Q | 4.30% | SMA50 | 4.01% | Rel Volume | 0.75 | Prev Close | 402.59 |
| Employees | 320,000 | LT Debt/Eq | -15.68 | Earnings | Oct 23 | SMA200 | -11.96% | Avg Volume | 1.67M | Price | 406.61 |
| IPO Date | Mar 10, 2011 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.40% 2.40% | Net Debt/EBITDA | 3.02 | Volume | 1,255,579 | Change | 1.00% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-28-26 | Reiterated | Goldman Sachs | Buy | $520 → $485 |
| Jul-27-26 | Reiterated | Deutsche Bank | Buy | $540 → $476 |
| Jul-27-26 | Reiterated | Robert W. Baird | $396 → $393 | |
| Jul-27-26 | Reiterated | Morgan Stanley | Underweight | $425 → $380 |
| Jul-27-26 | Reiterated | UBS | Buy | $635 → $579 |
| Jul-27-26 | Reiterated | Barclays | Equal Weight | $402 → $387 |
| Jul-27-26 | Reiterated | Keybanc | Overweight | $510 → $435 |
| Jul-27-26 | Reiterated | Oppenheimer | Outperform | $520 → $485 |
| Jul-20-26 | Reiterated | Wells Fargo | Equal Weight | $428 → $369 |
| Jul-16-26 | Reiterated | Barclays | Equal Weight | $427 → $402 |
HCA Healthcare, Inc., operating through its subsidiaries, delivers a comprehensive array of healthcare services throughout the United States. The organization manages a network of general and acute care hospitals that provide a full spectrum of medical and surgical care, encompassing inpatient services, intensive care, cardiac treatment, diagnostic procedures, and emergency services. These hospitals additionally offer a broad range of outpatient care, such as ambulatory surgery, laboratory testing, radiology, respiratory therapy, cardiology, and physical therapy. Beyond its hospital infrastructure, HCA Healthcare operates numerous specialized outpatient facilities. These include standalone ambulatory surgery centers, dedicated emergency care facilities, urgent care clinics, walk-in clinics, advanced diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology treatment facilities, physician practices, and various other healthcare sites. Furthermore, the company oversees psychiatric hospitals, which offer diverse therapeutic programs. These services cater to child, adolescent, and adult psychiatric care, alongside adolescent and adult alcohol and drug abuse treatment and counseling. As of December 31, 2021, HCA Healthcare's extensive portfolio included 182 hospitals, specifically 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals. Its network also featured 125 freestanding surgery centers and 21 freestanding endoscopy centers, all distributed across 20 states and England. Founded in 1968 and formerly known as HCA Holdings, Inc., the company's corporate headquarters are situated in Nashville, Tennessee.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 78,013 | 75,600 | 70,603 | 64,968 | 60,233 | 58,752 | 51,533 | 51,336 | 46,677 | |
| Cost of Goods Sold Incl. D&A | 55,892 | 44,226 | 41,925 | 39,389 | 37,056 | 36,260 | 8,369 | 8,481 | 7,724 | |
| Gross Profit | 22,121 | 31,374 | 28,678 | 25,579 | 23,177 | 22,492 | 43,164 | 42,855 | 38,953 | |
| Selling, General and Administrative Excl. Other | 16,573 | 7,997 | 31,170 | 29,487 | 27,685 | 26,779 | 23,874 | 23,560 | 21,425 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | -6,525 | 11,412 | -13,039 | -13,535 | -13,561 | -13,965 | 12,028 | 12,077 | 10,886 | |
| Operating Income | 12,073 | 11,965 | 10,547 | 9,627 | 9,053 | 9,678 | 7,262 | 7,218 | 6,642 | |
| Interest Expense | 2,316 | 2,248 | 2,061 | 1,938 | 1,739 | 1,529 | 1,560 | 1,841 | 1,765 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 114 | 115 | 37 | 17 | 1,266 | 1,684 | -272 | -133 | 458 | |
| Net Income Before Taxes | 9,871 | 9,832 | 8,523 | 7,706 | 8,580 | 9,833 | 5,430 | 5,244 | 5,335 | |
| Income Taxes | 2,018 | 2,050 | 1,866 | 1,615 | 1,746 | 2,112 | 1,043 | 1,099 | 946 | |
| Consolidated Net Income | 6,840 | 6,784 | 5,760 | 5,242 | 5,643 | 6,956 | 3,754 | 3,505 | 3,787 | |
| Net Income From Continuing Operations | 7,853 | 7,782 | 6,657 | 6,091 | 6,834 | 7,721 | 4,387 | 4,145 | 4,389 | |
| Net Income | 6,840 | 6,784 | 5,760 | 5,242 | 5,643 | 6,956 | 3,754 | 3,505 | 3,787 | |
| EPS (Recurring) | 29.96 | 28.62 | 22.27 | 19.24 | 19.44 | 21.51 | 11.08 | 10.27 | 11.04 | |
| EPS (Basic, Before Extraordinaries) | 29.96 | 28.62 | 22.27 | 19.24 | 19.44 | 21.51 | 11.08 | 10.27 | 11.04 | |
| EPS (Diluted) | 29.87 | 28.38 | 22.00 | 18.96 | 19.15 | 21.16 | 10.93 | 10.07 | 10.66 | |
| EBITDA | 15,835 | 15,603 | 13,896 | 12,721 | 13,290 | 14,252 | 9,735 | 9,664 | 9,368 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 13.61 | 16.45 | 13.64 | 14.28 | 12.53 | 12.14 | 15.05 | 14.68 | 11.67 | |
| Price To Sales Ratio | 1.16 | 1.43 | 1.10 | 1.13 | 1.16 | 1.41 | 1.08 | 0.98 | 0.91 | |
| Gross Margin | 28.36 | 41.50 | 40.62 | 39.37 | 38.48 | 38.28 | 83.76 | 83.48 | 83.45 | |
| Operating Margin | 15.48 | 15.83 | 14.94 | 14.82 | 15.03 | 16.47 | 14.09 | 14.06 | 14.23 | |
| Net Margin | 8.77 | 8.97 | 8.16 | 8.07 | 9.37 | 11.84 | 7.28 | 6.83 | 8.11 | |
| Shares Outstanding | 223 | 231 | 259 | 272 | 290 | 323 | 339 | 341 | 343 | |
| Market Capitalization | 90,674 | 107,845 | 77,739 | 73,625 | 69,588 | 82,985 | 55,752 | 50,403 | 42,686 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| McAlevey Michael R | EVP & Chief Legal & Admin Off. | Feb 18 '26 | Sale | 533.37 | 1,694 | 903,537 | 8,853 | Feb 18 |
| McAlevey Michael R | EVP & Chief Legal & Admin Off. | Feb 13 '26 | Option Exercise | 236.61 | 5,000 | 1,183,050 | 13,853 | Feb 18 |
| Berres Jennifer | SVP & Chief Human Res. Officer | Feb 11 '26 | Sale | 514.58 | 8,020 | 4,126,950 | 11,993 | Feb 12 |
| Wyatt Christopher F. | SVP & Controller | Feb 11 '26 | Sale | 505.00 | 4,000 | 2,020,000 | 44,379 | Feb 12 |
| Wyatt Christopher F. | SVP & Controller | Feb 05 '26 | Option Exercise | 139.06 | 10,670 | 1,483,770 | 51,737 | Feb 09 |
| Foster Jon M | EVP and COO | Feb 05 '26 | Option Exercise | 139.06 | 29,330 | 4,078,630 | 29,330 | Feb 09 |
| HAZEN SAMUEL N | CEO | Feb 03 '26 | Sale | 501.04 | 42,877 | 21,483,275 | 32,276 | Feb 05 |
| Cuffe Michael S. | EVP and Chief Clinical Officer | Feb 03 '26 | Sale | 498.09 | 1,500 | 747,135 | 30,003 | Feb 05 |
| HAZEN SAMUEL N | CEO | Jan 30 '26 | Option Exercise | 81.96 | 84,360 | 6,914,146 | 116,636 | Feb 02 |
| McAlevey Michael R | EVP & Chief Legal & Admin Off. | Nov 05 '25 | Sale | 473.79 | 3,892 | 1,843,991 | 3,487 | Nov 05 |
| McAlevey Michael R | EVP & Chief Legal & Admin Off. | Nov 03 '25 | Option Exercise | 236.61 | 13,170 | 3,116,154 | 16,657 | Nov 05 |
| HAZEN SAMUEL N | CEO | Oct 31 '25 | Option Exercise | 69.58 | 58,050 | 4,039,119 | 75,279 | Nov 04 |
| Cuffe Michael S. | EVP and Chief Clinical Officer | Sep 08 '25 | Sale | 418.84 | 3,836 | 1,606,670 | 31,503 | Sep 08 |
| Cuffe Michael S. | EVP and Chief Clinical Officer | Sep 04 '25 | Option Exercise | 173.12 | 10,920 | 1,890,470 | 42,423 | Sep 08 |
| Foster Jon M | EVP and COO | May 13 '25 | Sale | 369.32 | 15,698 | 5,797,661 | 12,646 | May 15 |